Skip to main
VYGR
VYGR logo

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 40%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc. is strategically positioned for long-term revenue growth through its co-commercialization options in key programs and a robust pipeline that includes innovative gene therapy solutions targeting severe neurological diseases. The company's TRACER platform has the potential to provide significant value for shareholders, supported by recent clinical advancements and a strong safety profile, which has seen no serious adverse events reported. Additionally, an extended cash runway into mid-2027 allows Voyager to focus on its Alzheimer’s programs, further enhancing its capacity to develop effective therapies that may outperform existing treatments in the market.

Bears say

Voyager Therapeutics is facing significant financial risks, evidenced by a reported net loss of ($1.13) per share and a lack of generated sales revenue, which delays the company's path to profitability. The potential for negative study results or adverse regulatory decisions poses an additional threat to the company's revenue projections and valuation estimates, particularly for its key programs like VY7523 and VY9323. Furthermore, intense competition in the therapeutic development space, with multiple tau antibody programs advancing ahead of VY7523, raises concerns about the company's ability to capture market share even if regulatory approvals are obtained.

Voyager Therapeutics (VYGR) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 40% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 20 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.